← Back to Home

Reducing Recurrent COPD Exacerbations: Merck Launches 2,136-Patient Phase 3 Trial of Ohtuvayre

Patients with COPD may still experience recurrent acute exacerbations despite maintenance treatment. A new study spanning 28 countries will follow patients for one year to test whether adding ensifentrine can further reduce this risk.

By SURL BioNews

For patients with chronic obstructive pulmonary disease (COPD), treatment aims not only to ease breathing but also to reduce episodes when the condition suddenly worsens. Merck & Co./MSD announced on November 3 that it had launched the Phase 3 ENHANCE-3 trial to investigate whether adding Ohtuvayre (ensifentrine) to standard treatment can reduce recurrent exacerbations in patients with a history of exacerbations.

The randomized study plans to enroll 2,136 people across 28 countries. Patients in both groups will continue receiving standard treatment, with either ensifentrine or placebo added, inhaled twice daily through a jet nebulizer for up to 52 weeks. The design seeks to answer how much additional protection another drug can provide for people who still experience acute exacerbations despite receiving treatment.

ClinicalTrials.gov data reproduced by Veeva show that the trial identifier is NCT07874815. Eligible participants are aged 40 to 80 and must have experienced at least one moderate or severe exacerbation in the past year while receiving standard treatment. Participants must have a smoking history of at least 10 pack-years; after bronchodilator use, their forced expiratory volume in one second (FEV1) must be at least 25% but less than 70% of the predicted normal value. These criteria also define the patient population to which the results will apply when interpreted later.

The study’s primary endpoint is the annualized rate of moderate or severe acute exacerbations confirmed by an adjudication committee, comparing the average frequency of episodes per year between the two groups. According to the company announcement and a MarketScreener report, the study will also assess lung function, health-related quality of life, severe exacerbations, and safety, allowing the assessment of drug efficacy to encompass the burden on patients’ daily lives as well as breathing measurements.

Ensifentrine inhibits both phosphodiesterase 3 and 4 (PDE3 and PDE4), combining bronchodilation and nonsteroidal anti-inflammatory activity in a single molecule. Ohtuvayre was approved by the U.S. Food and Drug Administration in June 2024 for maintenance treatment of COPD in adults. This study focuses on patients who have experienced exacerbations despite standard treatment, adding evidence on add-on treatment for this population.

There is currently a discrepancy in recruitment information: Merck says recruitment has begun in the United States and the first patients have entered the enrollment process, while the Veeva page still lists the study as “Not yet recruiting.” The two statuses are not yet aligned, and the company’s launch announcement cannot be interpreted as meaning that study sites in all 28 countries are open for enrollment.

Merck says it will share the results with regulatory authorities in various regions in the future. The information announced so far concerns the trial’s launch and design; no efficacy or safety data from ENHANCE-3 are yet available. How many exacerbations adding ensifentrine can prevent, and whether its benefits come with an acceptable treatment burden, remain questions for this one-year comparative study to answer.

References

  1. Merck & Co.
  2. MarketScreener
  3. Veeva Clinical Trials